I believe LLY is at a significant low point right now, making it a perfect entry for a swing trade. The potential of their weight loss drugs and the u...
Read
More
I believe LLY is at a significant low point right now, making it a perfect entry for a swing trade. The potential of their weight loss drugs and the upcoming market trends should drive the stock higher in the near future. I'm ready to buy some shares now and average down if it drops.
With the anticipated exponential growth in GLP-1 drug adoption over the next decade, I see LLY as a solid investment. Their leadership in the market p...
Read
More
With the anticipated exponential growth in GLP-1 drug adoption over the next decade, I see LLY as a solid investment. Their leadership in the market positions them well for future success, especially as new products and generic competition emerge.
Given the recent earnings misses and declines in forward-looking forecasts for LLY, I believe the company will continue to face pressure on its share ...
Read
More
Given the recent earnings misses and declines in forward-looking forecasts for LLY, I believe the company will continue to face pressure on its share price. The disconnect between treatment pricing and market demand due to affordability issues signals a challenging outlook for growth.
I'm feeling bullish on LLY right now as it seems primed to break out of its sideways consolidation. With strong potential to reach at least $970 if ea...
Read
More
I'm feeling bullish on LLY right now as it seems primed to break out of its sideways consolidation. With strong potential to reach at least $970 if earnings are solid, I'm holding on for a rebound following the report. The risk-reward is enticing here!
I'm considering moving from my tech-heavy portfolio to Eli Lilly, especially with the earnings report on 10/30 approaching. If they beat expectations,...
Read
More
I'm considering moving from my tech-heavy portfolio to Eli Lilly, especially with the earnings report on 10/30 approaching. If they beat expectations, I see a strong potential for LLY to soar even higher in the coming weeks.
I like this setup on LLY with PA standing on that 911.60 level below and looking to see if we can find 950 | 970 ahead. Now PA > 911.60 is key for this idea to be profitable.
I believe LLY is at a low point now and set to rise quickly due to strong product performance and market positioning. With significant advancements in...
Read
More
I believe LLY is at a low point now and set to rise quickly due to strong product performance and market positioning. With significant advancements in their insulin and cardiovascular drugs, this is definitely a buy for shares right now. It feels like a perfect entry point before it shoots up.
I believe Eli Lilly is on the brink of becoming the next trillion dollar company, with expected earnings growth of 120% this year and 40% next year. T...
Read
More
I believe Eli Lilly is on the brink of becoming the next trillion dollar company, with expected earnings growth of 120% this year and 40% next year. The diabetes drug approval in China is a game changer, and I see significant upside potential from here.
Eli Lilly's recent diabetes drug approval in China seems overrated. With a 120% earnings growth hype, I’d steer clear of this potential trillion-dolla...
Read
More
Eli Lilly's recent diabetes drug approval in China seems overrated. With a 120% earnings growth hype, I’d steer clear of this potential trillion-dollar stumble. Pass on this investment!
I see immense potential in Eli Lilly, especially with their recent diabetic drug approval in China. The 120% expected earnings growth this year makes ...
Read
More
I see immense potential in Eli Lilly, especially with their recent diabetic drug approval in China. The 120% expected earnings growth this year makes me believe they're on the path to become the next trillion-dollar company. Definitely considering a long-term investment here.
With Eli Lilly launching a more affordable version of its weight-loss drug Zepbound, potentially increasing market share and bolstering sales despite ...
Read
More
With Eli Lilly launching a more affordable version of its weight-loss drug Zepbound, potentially increasing market share and bolstering sales despite lower initial prices, combined with favorable outcomes in recent studies compared to competitors, LLY is positioned for strong long-term growth in the expanding anti-obesity market.
Eli Lilly (LLY) is showing bullish momentum. If it can close above $960, I strongly believe it will reach $1,000 soon. This is a good swing trade oppo...
Read
More
Eli Lilly (LLY) is showing bullish momentum. If it can close above $960, I strongly believe it will reach $1,000 soon. This is a good swing trade opportunity to capitalize on the upward trend.
With Eli Lilly's strong performance in the obesity and diabetes treatment market, positive study results for Tirzepatide, and recent analyst upgrades,...
Read
More
With Eli Lilly's strong performance in the obesity and diabetes treatment market, positive study results for Tirzepatide, and recent analyst upgrades, I believe LLY is well-positioned for long-term growth. Expanding research collaborations and distribution agreements further bolster my confidence in its future prospects.
Absolutely. I think it's a buy here. It's usually a thousand dollar stock. I think you would have wanted to buy it at $100. You'll want to buy it at $...
Read
More
Absolutely. I think it's a buy here. It's usually a thousand dollar stock. I think you would have wanted to buy it at $100. You'll want to buy it at $900. I still think you want to buy it even if it hits a thousand. This is a generational long-term haul. You want exposure to the GOP1 medicine right now. Lilly is number one in that space hands down.
Given the impressive initial results showing that tirzepatide can reduce the risk of developing Type 2 Diabetes by 94% in at-risk adults, I believe LL...
Read
More
Given the impressive initial results showing that tirzepatide can reduce the risk of developing Type 2 Diabetes by 94% in at-risk adults, I believe LLY has strong long-term growth potential. This breakthrough could significantly boost LLY’s revenues and market position in the coming years.
Challenging Eli Lilly's rosy outlook—earnings surprises often fade, and spikes in product sales can be short-lived. Might be wise to consider cashing ...
Read
More
Challenging Eli Lilly's rosy outlook—earnings surprises often fade, and spikes in product sales can be short-lived. Might be wise to consider cashing in gains soon!
Eli Lilly's mediocre performance, weak sales of weight loss and diabetes drugs, and outdated drug formulations hint at struggles ahead. Avoid expectin...
Read
More
Eli Lilly's mediocre performance, weak sales of weight loss and diabetes drugs, and outdated drug formulations hint at struggles ahead. Avoid expecting growth, especially with macroeconomic challenges.
Eli Lilly's impressive quarterly performance, driven by strong sales of weight loss and diabetes drugs, makes it a standout in the pharmaceutical sect...
Read
More
Eli Lilly's impressive quarterly performance, driven by strong sales of weight loss and diabetes drugs, makes it a standout in the pharmaceutical sector. Their advanced drug formulations and manufacturing capabilities suggest continued growth beyond macroeconomic factors.
With Eli Lilly's recent positive earnings report, increased full-year revenue outlook, and the FDA's clearance for Zepbound and Mounjaro, I believe LL...
Read
More
With Eli Lilly's recent positive earnings report, increased full-year revenue outlook, and the FDA's clearance for Zepbound and Mounjaro, I believe LLY will continue to perform well in the near term, making it a strong buy.
steady growth, driven by innovative drug development, a strong pipeline, robust financial performance, and a history of shareholder returns through di...
Read
More
steady growth, driven by innovative drug development, a strong pipeline, robust financial performance, and a history of shareholder returns through dividends and buybacks.